Chandan Healthcare

Quick check

The five things to look at first. Open one for more.

• DebtModerate safety, with cautionRated BBB- by CRISIL.
• ResultsGrowingIn the Jun 2026 quarter, sales rose 19% and profit rose 28% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersSteadyThe promoters (founders or parent) own 50% of the company, about the same as in Mar 2025.
• ValuationCheap vs its pastThe share trades at 20.9 times its yearly earnings (P/E), cheaper than 94% of the time in the last 2 years. Its usual P/E is about 26.

Chandan Healthcare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)20.9 against a typical 21: cheaper than most peers (1st = cheapest).17th of 34
• Sales growth+19.1% against a typical +19.1% from a year earlier.17th of 31
• Profit growth+27.9% against a typical +25.2% from a year earlier.10th of 24
• Share price, 3 months−2.6% against a typical −5.5%.12th of 33
• Size₹ 533.1 Cr. market value against a typical ₹ 83 Cr. (1st = largest).12th of 34

Exchange filings and their impact on the company.

• 13 Oct 2026General UpdatesHigh impactVery positivePrice +2.3% on 14 Oct
  Q2 diagnostics up 47% with 410 new franchises and a Rs 12 cr one-time stake-sale gain, sharply lifting forward earnings.

  Chandan Healthcare reported Q2 FY27 diagnostics revenue of Rs 56.38 cr, up 46.66% year-on-year, with total income of Rs 71.03 cr including a Rs 12.03 cr one-time gain from selling its stake in Chandan Pharmacy. Excluding that gain, total income still grew 43.89%. The company added 410 franchises in the quarter to reach 685, alongside 25 comprehensive centres and 44 diagnostic and radiology labs, signalling a sharp franchise-led scale-up.

  Full analysisFiling
• 6 Oct 2026General UpdatesLow impactPositivePrice +5.1% on 7 Oct
  Chandan sanctioned a Rs 5.22 cr ICICI loan to buy a Rs 5.8 cr CT scanner, a small debt-funded capacity addition.

  Chandan Healthcare has been sanctioned a Rs 5.22 crore medical equipment loan by ICICI Bank on 5 October 2026 to buy a 128-slice CT scanner costing Rs 5.8 crore. The bank will fund 90% of the cost, with the company contributing 10%, at 8.75% interest for 60 months including a 60-day moratorium, secured by the equipment. The scanner adds diagnostic capacity in its ordinary business and will modestly lift revenue and profit over the next year against a small rise in debt.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Rajeev Nain

Company Secretary

Asmita Singh

Managing Director (Promoter)